Double-stranded nucleotide compound for immune disease and use thereof

By designing specific sequences and modified double-stranded siRNAs, CFB gene expression can be efficiently suppressed, solving the problem of suppressing CFB expression in existing technologies and achieving significant therapeutic effects on CFB-related diseases.

WO2024245424A1PCT designated stage expired Publication Date: 2024-12-05VISIRNA THERAPEUTICS (SUZHOU) CO LTD

Patent Information

Application Number
PCT/CN2024/096814
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-05-30
Filing Date
2024-05-31
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Existing technologies are unable to effectively inhibit the expression of complement factor B (CFB), leading to various autoimmune and inflammatory diseases, such as atypical hemolytic uremic syndrome, age-related macular degeneration, C3 glomerulonephropathy, membranoproliferative glomerulonephritis, and IgA nephropathy. Traditional methods have shortcomings in terms of specificity, durability, and safety.

Method used

A double-stranded small interfering RNA (siRNA) composed of a sense strand and an antisense strand has been developed. These two strands are anti-complementary to form a double-stranded region with a length of 17 to 22 base pairs. It contains specific nucleotide sequence modifications and can be conjugated with ligand groups to target and inhibit CFB gene expression.

Benefits of technology

This siRNA exhibits highly efficient CFB mRNA inhibitory activity, with an inhibition rate of over 60% at a concentration of 10 nM in in vitro experiments and an inhibition rate of over 50% after 4 days of administration in in vivo experiments, without showing significant off-target effects, and significantly treats CFB expression-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024096814-FTAPPB-I100001
    Figure PCTCN2024096814-FTAPPB-I100001
  • Figure PCTCN2024096814-FTAPPB-I100002
    Figure PCTCN2024096814-FTAPPB-I100002
  • Figure PCTCN2024096814-FTAPPB-I100003
    Figure PCTCN2024096814-FTAPPB-I100003
Patent Text Reader

Abstract

Provided are a small interfering RNA for inhibiting complement factor B (CFB) expression, and a use of the small interfering RNA in preparation of a drug for treatment of CFB expression-related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

A double-stranded nucleotide compound for immune diseases and its application Technical Field

[0001] The present disclosure relates to the field of genetic engineering technology, and in particular to small interfering RNA expressing complement factor B (CFB) and its use in preparing drugs for treating diseases related to CFB expression. Background Art

[0002] RNA interference (RNAi) technology refers to a highly evolutionarily conserved phenomenon in which double-stranded RNA (dsRNA) induces the efficient and specific degradation of homologous mRNAs. It is a biological process in which RNA molecules inhibit the expression of a gene by destroying specific mRNAs. Because RNAi can specifically knock out or shut down the expression of specific genes, it has rapidly become one of the most sought-after research tools in gene function research and gene therapy. It has been widely used to explore gene function and treat metabolic and infectious diseases, as well as malignant tumors.

[0003] Under physiological conditions, the complement system acts as an important pillar of host defense by assisting in the rapid identification and elimination of microbial invaders. The complement system is an important component of the innate immune system and is composed of a group of 30 proteins that are synthesized by the liver and circulate in the blood as inactive precursors. The complement system is organized in three activation pathways: the classical pathway, the lectin pathway, and the alternative pathway (VM Holers, In Clinical Immunology: Principles and Practice, ed. RRR Rich, Mosby Press; 1996, 363-391). Abnormal complement system activation, insufficient regulation and control, and impaired and deteriorated effector function are the basis of many complement system-mediated diseases.

[0004] The alternative pathway is a magnesium-dependent cascade that is activated by the deposition and activation of the complement protein C3 on certain susceptible surfaces (e.g., cell wall polysaccharides of yeast and bacteria, and certain biopolymer materials). Spontaneous hydrolysis of C3 leads to the production of the potent anaphylatoxins C3a and C3b. C3b can then recruit nearby complement proteins to form a protease complex called C3 convertase (C3bBb). C3 convertase cleaves more C3 into C3a and C3b, forming an amplification loop and leading to the formation of the membrane attack complex (MAC). The MAC can create pores in the membrane of the target cell, leading to cell lysis and death.

[0005] Complement factor B (CFB) is a key player in the alternative pathway. Following complement activation, CFB is cleaved by factor D, generating the active enzyme C3 convertase. Therefore, CFB may be a suitable target for inhibiting complement pathway amplification, as its plasma concentration in humans is typically approximately 200-500 pg / mL (or approximately 2-5 pM). (PH Lesavre and HJ Müller-Eberhard. J. Exp. Med., 1978; 148: 1498-1510; JE Volanakis et al., New Eng. J. Med., 1985; 312: 395-401).

[0006] Mutations in CFB have been associated with various autoimmune and inflammatory diseases, including atypical hemolytic uremic syndrome (aHUS), a rare thrombotic microangiopathy characterized by microvascular thrombosis, hemolysis, and acute kidney injury; age-related macular degeneration (AMD), a common cause of vision loss in the elderly; C3 glomerulopathy, a rare kidney disease characterized by glomerular deposition of the complement component C3; and membranoproliferative glomerulonephritis (MPGN), a rare kidney disease characterized by thickening of the glomerular basement membrane and deposition of complement components. There is also evidence that CFB is involved in IgA nephropathy (IgAN) by promoting renal inflammation and tissue damage. Higher levels of CFB are associated with a more severe IgAN phenotype and worse outcomes, and genetic variants in the CFB gene have been associated with an increased risk of IgAN in certain populations. Several clinical trials of CFB small molecule inhibitors and antisense oligonucleotides have shown promising data in reducing proteinuria in IgAN. siRNA technology has been shown to offer significant advantages over traditional modalities in terms of improved specificity, durability, and safety. Targeting CFB with siRNA has the potential to provide excellent therapeutic agents in many autoimmune and inflammatory diseases.

[0007] Summary of the Invention

[0008] The present invention aims to discover and develop siRNA and its derivatives that can inhibit and / or reduce CFB expression.

[0009] The first aspect of the present invention provides an siRNA comprising a sense strand and an antisense strand, wherein the sense strand and the antisense strand comprise a double-stranded region formed by reverse complementation. In some embodiments of the first aspect of the present invention, at least a portion of the sense strand and at least a portion of the antisense strand are reversely complementary to each other and form a double-stranded region. In some embodiments of the first aspect of the present invention, the double-stranded region is 17 to 22 base pairs in length. In some embodiments of the first aspect of the present invention, the double-stranded region is 21 base pairs in length.

[0010] In some embodiments of the first aspect of the present invention, the sense strand comprises a sequence as shown in any one of SEQ ID NOs. 1-96 and SEQ ID NOs: 194-195. In some embodiments of the first aspect of the present invention, the sense strand of the siRNA comprises 17 to 22 consecutive bases of a sequence as shown in any one of SEQ ID NOs: 1-96 and SEQ ID NOs: 194-195. In some embodiments of the first aspect of the present invention, the sense strand of the siRNA comprises 17, 18, 19, 20, 21 or 22 consecutive bases of a sequence as shown in any one of SEQ ID NOs: 1-96 and SEQ ID NOs: 194-195. In some embodiments of the first aspect of the present invention, the sense strand of the siRNA comprises 20 consecutive bases of a sequence as shown in any one of SEQ ID NOs: 1-96.

[0011] In some embodiments of the first aspect of the present invention, the antisense strand comprises a sequence as shown in any one of SEQ ID NOs: 97-192 and SEQ ID NOs: 196-197. In some embodiments of the first aspect of the present invention, the antisense strand of the siRNA comprises 17 to 22 consecutive bases of a sequence as shown in any one of SEQ ID NOs: 97-192 and SEQ ID NOs: 196-197. In some embodiments of the first aspect of the present invention, the antisense strand of the siRNA comprises 17, 18, 19, 20, 21 or 22 consecutive bases of a sequence as shown in any one of SEQ ID NOs: 97-192 and SEQ ID NOs: 196-197. In some embodiments of the first aspect of the present invention, the antisense strand of the siRNA comprises 20 consecutive bases of a sequence as shown in any one of SEQ ID NOs: 97-192 and SEQ ID NOs: 196-197.

[0012] In some embodiments of the first aspect of the present invention, the sense strand contained in the siRNA contains 17 to 22 consecutive bases of a sequence as shown in any one of SEQ ID NOs: 1-96 and SEQ ID NOs: 194-195, and the antisense strand contained in the siRNA contains 17 to 22 consecutive bases of a sequence as shown in any one of SEQ ID NOs: 97-192 and SEQ ID NOs: 196-197, and at least a portion of the sense strand and at least a portion of the antisense strand are reversely complementary to form a double-stranded region, and the length of the double-stranded region is 17 to 22 base pairs.

[0013] In some embodiments of the first aspect of the present invention, the sense strand of the siRNA comprises 17 to 21 consecutive bases (further 20 consecutive bases) of the sequence shown in SEQ ID NO: 20, SEQ ID NO: 194, or SEQ ID NO: 195, and the antisense strand comprises 17 to 21 consecutive bases (further 20 consecutive bases) of the sequence shown in SEQ ID NO: 116, SEQ ID NO: 196, or SEQ ID NO: 197. In some embodiments, the sense strand of the siRNA comprises the sequence shown in SEQ ID NO: 20, and the antisense strand comprises the sequence shown in SEQ ID NO: 116. In some embodiments, the sense strand of the siRNA comprises the sequence shown in SEQ ID NO: 195, and the antisense strand comprises the sequence shown in SEQ ID NO: 197. In some embodiments, the sense strand of the siRNA comprises the sequence shown in SEQ ID NO: 20, and the antisense strand comprises the sequence shown in SEQ ID NO: 197.

[0014] In some embodiments of the first aspect of the invention, the sense strand of the siRNA comprises the nucleotide sequence of the sense strand of an siRNA molecule as shown in Table 2, and the antisense strand comprises the nucleotide sequence of the antisense strand of the same siRNA molecule as shown in Table 2. In certain embodiments, the siRNA has one or more modified nucleotides, and the modified nucleotides can be at any suitable position of the sense strand and / or antisense strand of the siRNA. In certain embodiments, the siRNA has one or more modified nucleotides, and the modified nucleotides are at the modified nucleotide positions of the corresponding siRNA molecule in Table 2. In certain embodiments, the siRNA has the same nucleotide sequence as the corresponding siRNA molecule in Table 2, and has the modified nucleotides at the same positions. In certain embodiments, the siRNA has the same nucleotide sequence as the corresponding siRNA molecule in Table 2, and has the same modified nucleotides at the same positions.

[0015] In some embodiments, the siRNA comprises:

[0016] a) a sense strand (5'→3') containing the following nucleotide sequence: gaauuccuGfAfAfuuuuaugacu, and an antisense strand (5'→3') containing the following nucleotide sequence: a*Gf*u*CfaUfaaaauUfcAfgGfaAfuUf*c,

[0017] b) a sense strand (5'→3') containing the following nucleotide sequence: gaauuccuGfAfAfuuuuaugaca, and an antisense strand (5'→3') containing the following nucleotide sequence: u*Gf*Uf*CfauaaaauUfcAfgGfaauu*c,

[0018] c) a sense strand (5'→3') comprising the following nucleotide sequence: gaauuccuGfAfAfuuuuaugacu, and an antisense strand (5'→3') comprising the following nucleotide sequence: u*Gf*Uf*CfauaaaauUfcAfgGfaauu*c,

[0019] Wherein, * indicates that two nucleotides are connected by a phosphorothioate bond, lowercase letters (e.g., a, u, g, c) indicate that the ribose of the nucleotide is modified by 2'-methoxy (i.e., 2'-O-methyl), and capital letters A, U, C, G, and T are followed by "f" to indicate that the ribose of the nucleotide is modified by 2'-fluoro.

[0020] In some embodiments, the siRNA further comprises abasic nucleotides at the 3' and / or 5' end of the sense strand or antisense strand, optionally, inverted abasic nucleotides. In some embodiments, the abasic nucleotides or inverted abasic nucleotides are connected to the 3' and / or 5' end of the sense strand or antisense strand through phosphorothioate. In some embodiments, the siRNA further comprises 5' vinylphosphonate (VP) at the 5' end of the antisense strand and is modified. In some embodiments, the VP modification is connected to the 5' end of the antisense strand through phosphorothioate.

[0021] In some embodiments, the siRNA comprises:

[0022] a) a sense strand (5'→3') containing the following nucleotide sequence: (invAb)*gaauuccuGfAfAfuuuuaugacu*(invAb), and an antisense strand (5'→3') containing the following nucleotide sequence: a*Gf*u*CfaUfaaaauUfcAfgGfaAfuUf*c,

[0023] b) a sense strand (5'→3') comprising the following nucleotide sequence: (invAb)*gaauuccuGfAfAfuuuuaugaca*(invAb), and an antisense strand (5'→3') comprising the following nucleotide sequence: V Pu*Gf*Uf*CfauaaaauUfcAfgGfaauu*c,

[0024] c) a sense strand (5'→3') comprising the following nucleotide sequence: (invAb)*gaauuccuGfAfAfuuuuaugacu*(invAb), and an antisense strand (5'→3') comprising the following nucleotide sequence: cPrPu*Gf*Uf*CfauaaaauUfcAfgGfaauu*c,

[0025] Wherein, * indicates that the two nucleotides are connected by a phosphorothioate bond, lowercase letters (e.g., a, u, g, c) indicate that the ribose of the nucleotide is modified by 2'-methoxy (i.e., 2'-O-methyl), uppercase letters A, U, C, G, and T are followed by "f" and indicate that the ribose of the nucleotide is modified by 2'-fluorine, invAb indicates an inverted abasic nucleotide, VP indicates vinyl phosphonate, and cPrP indicates cyclopropyl phosphonate.

[0026] In some embodiments, the siRNA further comprises a ligand group at the 3' and / or 5' end of the sense strand. Any suitable ligand group can be used. In some embodiments, the siRNA further comprises a ligand group provided herein at the 3' and / or 5' end of the sense strand, such as, but not limited to, L96 or NAG37. In some embodiments, the siRNA further comprises a ligand group provided herein at the 3' end of the sense strand, such as, but not limited to, L96 or NAG37.

[0027] In some embodiments of the first aspect of the present invention, the siRNA is selected from dS183-dS278, as shown in Table 2. In some embodiments of the first aspect of the present invention, the siRNA is selected from dS183, dS184, dS185, dS186, dS187, dS188, dS189, dS190, dS191, dS192, dS193, dS194, dS195, dS196, dS197, dS198, dS199, dS200, dS201, dS202, dS203, dS204, dS205, dS206, dS207, dS208, dS209, dS210, dS211, dS212, dS213, dS214, dS215, dS216, dS217, dS218, dS219, dS220, dS221, dS222, dS223, dS224, dS225, dS226, dS227, dS228, dS229, dS230, dS231, dS232, dS233, dS234, dS235, dS236, dS237, dS238, dS239, dS240, dS241, dS242, dS243, dS244, dS245, dS246, dS247, dS248, dS249, dS250, dS251, dS252, dS253, dS254, dS255, dS256, dS257, dS258, dS259, dS260, dS261, dS262, dS263, dS264, dS265, dS266, dS267, dS268, dS269, dS270, dS271, dS272, dS273, dS274, dS275, dS276, dS277, dS278, dS289, dS290, dS291, dS292, dS293, dS294, dS295, dS296, dS297, dS298, dS299 or dS300.

[0028] In the second aspect of the present invention, a siRNA conjugate is provided, which comprises the siRNA as described in the scheme of the first aspect of the present invention and a ligand group, wherein the ligand group is conjugated to the siRNA, and the ligand group comprises 1, 2, 3 or 4 GalNAc groups, and the number of the ligand groups is 1, 2, 3, 4, 5, 6 or 7.

[0029] In some embodiments of the second aspect of the present invention, the number of the ligand group is one.

[0030] In some embodiments of the second aspect of the present invention, the ligand group comprises three GalNAc groups. In some embodiments of the second aspect of the present invention, the ligand group comprises the structure of L96. In some embodiments of the second aspect of the present invention, the ligand group comprises the structure of NAG37.

[0031] In some embodiments of the second aspect of the invention, the siRNA conjugate is selected from dS308, dS309, dS310, dS311, dS323, dS326, dS327, dS328, dS329, dS330, dS331, dS332, dS333 or dS334.

[0032] The third aspect of the present invention provides a pharmaceutical composition, which comprises the siRNA as described in the scheme of the first aspect of the present invention or the siRNA conjugate as described in the scheme of the second aspect of the present invention and a pharmaceutically acceptable carrier.

[0033] The fourth aspect of the present invention provides use of the siRNA described in the scheme of the first aspect of the present invention, the siRNA conjugate described in the scheme of the second aspect of the present invention, or the pharmaceutical composition described in the scheme of the third aspect of the present invention in the preparation of a drug for treating diseases related to CFB expression.

[0034] In some embodiments of the fourth aspect of the present invention, the disease associated with CFB expression is a disease caused by abnormal complement activation.

[0035] In some embodiments of the fourth aspect of the present invention, the disease associated with CFB expression is IgA nephropathy.

[0036] In a fifth aspect, the present invention provides a method for treating diseases and / or conditions associated with CFB expression, wherein the method comprises administering a therapeutically effective amount of the above-mentioned siRNA, siRNA conjugate and / or pharmaceutical composition to a subject in need thereof.

[0037] In some embodiments of the fifth aspect of the present invention, the disease associated with CFB expression is a disease caused by abnormal complement activation.

[0038] In some embodiments of the fifth aspect of the present invention, the disease associated with CFB expression is IgA nephropathy.

[0039] In a sixth aspect, the present invention provides a method for inhibiting the expression of the CFB gene in a cell, comprising contacting the cell with an effective amount of the above-mentioned siRNA, siRNA conjugate and / or pharmaceutical composition, thereby inhibiting the expression of the CFB gene in the cell.

[0040] As described above, in addition to their administration, the siRNA and / or siRNA conjugates characterized herein can be administered in combination with other known agents that effectively inhibit CFB expression. In any case, the administering physician can adjust the amount and timing of siRNA and / or siRNA conjugate administration based on the results observed using standard efficacy measurements known in the art or described herein.

[0041] In the present invention:

[0042] Table 1.1 Sequences involved in the present invention

[0043] Table 1.2 Sequences involved in the present invention

[0044] The present invention provides siRNAs and siRNA conjugates as shown in the table below. The following sequences are written and read in the 5' to 3' direction. The abbreviations or abbreviations used in this table are as follows: (invAb) is an inverted abasic ribonucleic acid, * indicates that the two nucleotides are connected by a phosphorothioate bond, lowercase letters (e.g., a, u, g, c) indicate that the nucleotide is modified with a 2'-methoxy (i.e., 2'-O-methyl) group, uppercase letters A, U, C, G, and T are followed by an "f" to indicate that the nucleotide is modified with a 2'-fluoro group, VP is vinylphosphonate, cPrP is cyclopropylphosphonate, and L96 represents a ligand group with the following structure:

[0045] NAG37 represents a ligand group of the following structure:

[0046] Table 2 siRNAs involved in the present invention Beneficial effects

[0047] The siRNA, siRNA conjugate and pharmaceutical composition provided by the present invention have good stability, high CFB mRNA inhibitory activity, low off-target effect, and / or can significantly treat diseases and / or disorders related to CFB expression.

[0048] The siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention exhibit excellent target gene inhibition activity in in vitro experiments. In some embodiments, the target gene is CFB.

[0049] The siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show excellent target gene inhibitory activity in in vitro experiments. In some embodiments, the siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show an inhibitory activity of greater than or equal to 60%, 70%, 80%, 85%, 90%, 91%, 92% or 93% on the target gene at a concentration of 10 nM in in vitro experiments. In some embodiments, the siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show an inhibitory activity of greater than or equal to 60%, 70%, 80% or 85% on the target gene at a concentration of 1 nM in in vitro experiments. In some embodiments, the siRNA or siRNA conjugate provided by the present invention shows an inhibitory activity of greater than or equal to 40%, 50%, 60%, 70% or 80% on the target gene at a concentration of 0.5 nM in in vitro experiments. In some embodiments, the siRNA or siRNA conjugate provided by the present invention shows an inhibitory activity of greater than or equal to 5%, 10%, 20%, 30%, 40%, 50% or 60% on the target gene at a concentration of 0.1 nM in in vitro experiments. In some embodiments, the siRNA or siRNA conjugate provided by the present invention shows an IC 50 In some embodiments, the siRNA or siRNA conjugates provided by the present invention show the inhibitory activity to the target gene in vitro experiments, which is the reduction of the expression level of the target gene mRNA measured by qPCR. In some embodiments, the siRNA or siRNA conjugates provided by the present invention show the inhibitory activity to the target gene in vitro experiments, which is measured in human liver cancer cells (such as Huh7 cells). In some embodiments, the siRNA or siRNA conjugates provided by the present invention show the inhibitory activity to the target gene in vitro experiments, which is measured in human liver cells (such as primary human liver cells (PHH)). In some embodiments, the siRNA or siRNA conjugate provided by the present invention shows inhibitory activity against the target gene in an in vitro experiment, which is measured by the method described in Example 2 or 3. In some embodiments, the target gene is CFB.

[0050] The siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention exhibit excellent target gene inhibition activity in in vivo experiments. In some embodiments, the target gene is CFB.

[0051] In some embodiments, the siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show an average inhibition rate of greater than or equal to 50%, 60%, 70%, 80%, 90%, 95% or 97% of the target gene in in vivo experiments after 4 days of administration. In some embodiments, the siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show an average inhibition rate of greater than or equal to 50%, 60%, 70%, 80% or 85% of the target gene in in vivo experiments after 15 days of administration. In some embodiments, the siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show inhibitory activity on the target gene in in vivo experiments, which is measured by qPCR to reduce the expression level of the target gene mRNA in the liver of a mouse model of high-pressure tail vein injection of a human target gene plasmid. In some embodiments, the siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show inhibitory activity on the target gene in in vivo experiments, which is measured by the method described in Example 4.

[0052] In some embodiments, the siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show an average inhibition rate of greater than or equal to 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 85% of the target gene in in vivo experiments after 28 days of administration. In some embodiments, the siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show inhibitory activity on the target gene in in vivo experiments, which is a reduction in the expression level of the target gene mRNA in the serum, fundus or liver of human CFB knock-in mice (hCFB) measured by qPCR. In some embodiments, the siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show inhibitory activity on the target gene in in vivo experiments, which is measured by the method described in Example 5.

[0053] In some embodiments, the siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show an average inhibition rate of greater than or equal to 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 85% of the target gene in in vivo experiments at 28 days of administration. In some embodiments, the siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show an average inhibition rate of greater than or equal to 10%, 20%, 30%, 40%, 50%, 60%, 70% or 75% of the target gene in in vivo experiments at 56 days of administration. In some embodiments, the siRNA, siRNA conjugates and pharmaceutical compositions provided by the present invention show an average inhibition rate of greater than or equal to 10%, 20%, 30%, 40%, 50%, 60%, 70% or 75% of the target gene in in vivo experiments at 122 days of administration. In some embodiments, the siRNAs, siRNA conjugates, and pharmaceutical compositions provided herein exhibit inhibitory activity against target genes in in vivo experiments, as measured by reduction in target gene mRNA expression levels in serum or liver of cynomolgus monkeys, as measured by qPCR. In some embodiments, the siRNAs, siRNA conjugates, and pharmaceutical compositions provided herein exhibit inhibitory activity against target genes in in vivo experiments, as measured by the method described in Example 6.

[0054] The siRNAs, siRNA conjugates, and pharmaceutical compositions provided herein do not exhibit significant off-target effects. Off-target effects can, for example, inhibit normal gene expression of non-target genes. It is considered that an off-target effect is insignificant if the binding / inhibition of off-target gene expression is less than 50%, 40%, 30%, 20%, or 10% compared to the on-target effect.

[0055] definition

[0056] Unless otherwise specified, the following terms and phrases used herein are intended to have the following meanings. The absence of a specific definition for a term or phrase should not be construed as indefinite or unclear, but rather should be understood in accordance with its ordinary meaning. When a trade name appears herein, it is intended to refer to the corresponding commercial product or active ingredient.

[0057] In the present invention, "optional" or "optionally" means that the event or situation described thereafter may or may not occur, and the description includes instances where the event or situation occurs and instances where it does not occur. For example, "optionally substituted" "alkyl" includes "alkyl" and "substituted alkyl" as defined below. It will be understood by those skilled in the art that, for any group containing one or more substituents, these groups are not intended to introduce any substitution or substitution pattern that is sterically impractical, synthetically unfeasible, and / or inherently unstable.

[0058] In the present invention, "subject" refers to any animal, such as a mammal or marsupial. The subject of the present invention includes, but is not limited to, humans, non-human primates (e.g., rhesus monkeys or other types of macaques), mice, pigs, horses, cattle, rats, or any kind of poultry.

[0059] As used herein, "treatment" refers to an approach for obtaining beneficial or desired results, including but not limited to a therapeutic benefit. "Therapeutic benefit" means eradication or amelioration of the underlying disorder being treated. Furthermore, a therapeutic benefit is achieved by eradication or amelioration of one or more physiological symptoms associated with the underlying disorder, such that an improvement is observed in the subject, even though the subject may still be afflicted with the underlying disorder.

[0060] In the present invention, siRNA or siRNA conjugates can be used to treat diseases. In some embodiments of the present invention, the disease is a drug for a disease associated with CFB expression. In some embodiments of the present invention, the disease associated with CFB expression is an autoimmune disease. In some embodiments of the present invention, the disease associated with CFB expression is an autoimmune disease caused by complement activation. In some embodiments of the present invention, the disease associated with CFB expression is IgA nephropathy.

[0061] In the present invention, "small interfering RNA", "siRNA", "RNAi" or "iRNA agent" are used interchangeably to refer to a double-stranded ribonucleic acid molecule that is long enough to trigger an interferon response and enter RISC (RNAi-induced silencing complex) and short enough so that it does not induce a harmful interferon response in human cells (for example, an siRNA agent or its cleavage product can down-regulate a target gene by, for example, inducing RNAi about a target RNA, wherein the target may include an endogenous or pathogenic target RNA). In some embodiments of the present invention, the siRNA is at least partially complementary to a coding sequence in a target gene expressed in a cell. In some embodiments of the present invention, after the siRNA is delivered to a cell expressing a gene, the siRNA is able to inhibit or block the expression of the gene in vitro or in vivo. Typically, the siRNA comprises a double-stranded region of less than 60, 50, 40 or 30 complementary base pairs; preferably, it comprises a double-stranded region of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22 complementary base pairs. In some embodiments of the present invention, the sense strand and antisense strand of the siRNA are independently 15-30 nucleotides in length, and the length of the complementary double-stranded region formed is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22 base pairs. In some embodiments of the present invention, the sense strand and antisense strand of the siRNA are fully complementary and paired, and have a length of 15-30 base pairs. In some embodiments of the present invention, the sense strand and antisense strand of the siRNA are fully complementary and paired, and have a length of 17, 18, 19, 20, 21 or 22 base pairs.

[0062] In the present invention, siRNA "targeting" the target gene (or a specified segment of the target gene) means that the antisense strand of the siRNA is at least partially complementary to at least a portion of the RNA transcribed from the target gene (or a specified segment thereof). In some embodiments of the present invention, the siRNA provided by the present invention targets the complement factor B (CFB) gene. In some embodiments of the present invention, the antisense strand of the siRNA provided by the present invention is at least partially complementary to the targeted segment of the RNA transcribed from the CFB gene. In some embodiments of the present invention, the antisense strand of the siRNA provided by the present invention is fully complementary to the targeted segment of the RNA transcribed from the CFB gene.

[0063] The position of the targeted fragment of the CFB gene targeted by the antisense strand of the siRNA provided by the present invention can be based on the position in the CFB gene transcript. In some embodiments of the present invention, the accession number of the CFB gene transcript in the NCBI data is NM_001710.6. In some embodiments of the present invention, the sequence of the CFB gene transcript is as shown in SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets any continuous 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 1-70 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets any continuous 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 29-51 of SEQ ID NO: 193.

[0064] In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 200-400 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 235-255 or 333-353 of SEQ ID NO: 193.

[0065] In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 400-600 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 447-470, 479-553, or 579-599 of SEQ ID NO: 193.

[0066] In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 650-700 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 672-692 of SEQ ID NO: 193.

[0067] In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 750-850 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 778-798 and 845-866 of SEQ ID NO: 193.

[0068] In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 900-1250 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 919-970, 985-1105, and 1152-1224 of SEQ ID NO: 193.

[0069] In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 1250-1300 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 1261-1291 of SEQ ID NO: 193.

[0070] In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 1300-1500 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 1313-1350, 1385-1411, or 1431-1488 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 1431-1451 or 1432-1452 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets the nucleotide sequence at positions 1431-1450, 1431-1451, 1432-1451 or 1432-1452 of SEQ ID NO:193.

[0071] In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 1500-1600 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 1537-1557 of SEQ ID NO: 193.

[0072] In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 1600-1700 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 1603-1623 or 1667-1692 of SEQ ID NO: 193.

[0073] In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 1800-1900 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 1826-1879 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 1826-1846, 1830-1850, 1838-1858, 1858-1878, or 1859-1879 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets the nucleotide sequence of positions 1826-1845, 1826-1846, 1830-1849, 1830-1850, 1838-1857, 1838-1858, 1858-1877, 1858-1878, 1859-1878 or 1859-1879 of SEQ ID NO:193.

[0074] In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 1900-2500 of SEQ ID NO: 193. In some embodiments of the present invention, the siRNA provided by the present invention targets any consecutive 17 to 22 (e.g., 20 or 21) nucleotide sequences in positions 1943-2026, 2050-2103, 2111-2210, 2222-2306, 2330-2419, or 2448-2474 of SEQ ID NO: 193.

[0075] In the present invention, "inhibit" refers to a decrease in gene expression when the cell, cell population, or tissue is treated with the siRNA, siRNA conjugate, and pharmaceutical composition of the present invention, compared to a cell, cell population, or tissue that has not been treated in this manner. The terms "inhibit," "reduce," "silence," "downregulate," "suppress," and other similar terms used herein are used interchangeably and encompass any level of inhibition. Preferably, inhibition includes statistically significant inhibition or clinically significant inhibition.

[0076] In the present invention, "conjugation" refers to the connection between two or more chemical moieties, each of which has a specific function, in a covalently linked manner; accordingly, "conjugate" refers to a compound formed by covalently linking the chemical moieties. Furthermore, "siRNA conjugate" refers to a compound formed by covalently linking one or more chemical moieties (such as ligand groups) with specific functions to siRNA. In this article, the siRNA conjugate of the present invention is sometimes referred to as "conjugate", which should be understood as the full name of the siRNA conjugate according to the context. In some embodiments of the present invention, the ligand group can be connected to the phosphate group of any nucleotide of the siRNA (including the covalent connection of the ligand group to the atom at the 3' or 5' position of the nucleotide through a phosphodiester bond), the 2'-hydroxyl group, the 5'-hydroxyl group or the base. In some embodiments of the present invention, the ligand group can also be connected to the 3'-hydroxyl group, in which case the nucleotides are connected using a 2'-5' phosphodiester bond.

[0077] In the present invention, "ligand group" refers to a pharmaceutically acceptable scaffold group and at least one targeting group, and the siRNA, the scaffold group and the targeting group are connected in sequence, i.e., "siRNA-scaffold group-targeting group". In some embodiments, the targeting groups are 2-4. The siRNA molecule can be non-covalently or covalently conjugated to the ligand group, for example, it can be covalently conjugated to the ligand group. The conjugation site of the siRNA and the ligand group can be at the 3' end or 5' end of the siRNA sense strand, or in the internal sequence of the siRNA. In some embodiments, the conjugation site of the siRNA and the ligand group is at the 3' end or 5' end of the siRNA sense strand.

[0078] In the present invention, "targeting group" refers to a targeting agent for cells or tissues of an animal or human body, such as a lectin, glycoprotein, lipid or protein (e.g., antibody) that binds to a specific cell type, such as renal cells. The targeting group can be thyroid stimulating hormone, melanocyte stimulating hormone, lectin, glycoprotein, surfactant protein A, mucin carbohydrate, multivalent lactose, multivalent galactose, N-acetyl-galactosamine (i.e., GalNAc), N-acetyl-glucosamine multivalent mannose, multivalent fucose, glycosylated polyamino acids, multivalent galactose, transferrin, bisphosphonates, polyglutamic acid, polyaspartic acid, lipids, cholesterol, steroids, bile acid, folic acid, vitamin B12, biotin, RGD peptide, RGD peptide mimetic or aptamer.

[0079] In the present invention, a "scaffold group" refers to a structure that connects two parts of a compound, typically including a direct bond or an atom such as oxygen or sulfur, a unit such as -NR-, -C(=O)-, -C(=O)NH-, -S(=O)-, -SO2-, -SO2NH-, or an atom chain such as substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, arylalkyl, arylalkenyl, arylalkynyl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocycloalkyl, heterocycloalkenyl, heterocycloalkynyl, aryl, heteroaryl, heterocyclo, cycloalkyl, cycloalkenyl, alkylarylalkyl, alkylarylalkenyl, alkylarylalkynyl, alkenylarylalkyl, alkenylarylalkenyl, alkenylarylalkynyl, alkynylarylalkyl, alkynylarylalkenyl, alkynylarylalkynyl, alkylheteroarylalkyl, alkylheteroaryl wherein one or more methylene radicals may be interrupted or terminated by —O—, —S—, —S(═O)—, —SO—, —N(R)—, —C(═O)—, a cleavable linking group, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, or a substituted or unsubstituted heterocyclyl; and wherein R is hydrogen, acyl, aliphatic, or substituted aliphatic. The scaffold group can be a divalent, trivalent, tetravalent, pentavalent, hexavalent or more valent group. The scaffold group contains 0, 1, 2 or 3 branch points. In some embodiments of the present invention, the branch point is C, CH, -CH2-, N, -NH-, -O-, -S-, -C(=O)-. In some embodiments of the present invention, the scaffold group is tetravalent, the scaffold group has 1 branch point; further, the scaffold group is In some embodiments of the present invention, the scaffold group is divalent and has 0 branch points; further, the scaffold group is

[0080] In some embodiments of the present invention, the ligand group is [NAG37], and the siRNA conjugate has the structure shown below:

[0081] In some embodiments of the present invention, the ligand group is [L96], and the siRNA conjugate has the structure shown below:

[0082] In the present invention, "complementary" or "reverse complementary" are used interchangeably and refer to a structural relationship between two nucleotides (e.g., on two opposing nucleic acid chains or on opposing regions of a single nucleic acid chain) that allows the two nucleotides to form base pairs with each other (e.g., a purine nucleotide of a nucleic acid that is complementary to a pyrimidine nucleotide of an opposing nucleic acid can form base pairs together by forming hydrogen bonds with each other). In some embodiments of the present invention, complementary nucleotides can form base pairs in a Watson-Crick manner or in any other manner that allows the formation of a stable duplex. In some embodiments of the present invention, two nucleic acid chains may have multiple double-stranded regions that form complementarity. In some embodiments of the present invention, in DNA, adenine (A) always pairs with thymine (T), in RNA, adenine (A) pairs with uracil (U); and guanine (G) always pairs with cytosine (C).

[0083] In the present invention, "mismatch" refers to the situation in which the bases at corresponding positions in a double-stranded nucleic acid molecule are not paired in a complementary manner.

[0084] In the present invention, all chains / sequences are written and read in the 5' to 3' direction.

[0085] In the present invention, siRNA can include one or more modified nucleotides. In some embodiments, the sense strand of siRNA can include one or more modified nucleotides. In the present invention, the sense strand of siRNA can include 1 to 21, 1 to 20, 1 to 19, 1 to 18, 1 to 17, 1 to 16, 1 to 15, 1 to 14, 1 to 13, 1 to 12, 1 to 11, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3 or 1 to 2 modified nucleotides. In some embodiments, the sense strand of siRNA can include 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 modified nucleotides. In some aspects, the sense strand of the siRNA can include 20 to 21, 19 to 21, 18 to 21, 17 to 21, 16 to 21, 15 to 21, 14 to 21, 13 to 21, 12 to 21, 11 to 21, 10 to 21, 9 to 21, 8 to 21, 7 to 21, 6 to 21, 5 to 21, 4 to 21, 3 to 21, 2 to 21, or 1 to 21 modified nucleotides.

[0086] In some embodiments, the antisense strand of the siRNA may include one or more modified nucleotides. In the present invention, the antisense strand of the siRNA may include 1 to 21, 1 to 20, 1 to 19, 1 to 18, 1 to 17, 1 to 16, 1 to 15, 1 to 14, 1 to 13, 1 to 12, 1 to 11, 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3 or 1 to 2 modified nucleotides. In some embodiments, the antisense strand of the siRNA may include 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 modified nucleotides. In some aspects, the antisense strand of the siRNA can include 20 to 21, 19 to 21, 18 to 21, 17 to 21, 16 to 21, 15 to 21, 14 to 21, 13 to 21, 12 to 21, 11 to 21, 10 to 21, 9 to 21, 8 to 21, 7 to 21, 6 to 21, 5 to 21, 4 to 21, 3 to 21, 2 to 21, or 1 to 21 modified nucleotides.

[0087] In some embodiments, the sense strand of the siRNA includes 21 modified nucleotides, and the antisense strand includes 21 modified nucleotides. In some embodiments, the sense strand of the siRNA includes 21 modified nucleotides, and the antisense strand includes 21 modified nucleotides, and neither the sense strand nor the antisense strand includes natural nucleotides.

[0088] In the present invention, "G," "C," "A," "T," and "U" refer to nucleotides containing guanine, cytosine, adenine, thymine, and uracil as bases. In the present invention, the presence of "d" before A, U, C, G, and T indicates 2'-deoxyribonucleic acid, while the absence of "d" indicates ribonucleic acid. For example, dA represents deoxyadenine, dU represents deoxyuracil, dC represents deoxycytosine, dG represents deoxyguanine, and dT represents deoxythymine. In the present invention, the presence of "f" after A, U, C, G, and T indicates that the nucleotide is modified with 2'-fluorine. For example, Af represents 2'-fluoroadenine, Uf represents 2'-fluorouracil, Cf represents 2'-fluorocytosine, Gf represents 2'-fluoroguanine, and Tf represents 2'-fluorothymine. Lowercase letters (e.g., a, u, g, c) indicate that the nucleotide is modified with a 2'-methoxy group (i.e., 2'-O-methyl), for example, a is 2'-methoxyadenine, u is 2'-methoxyuracil, c is 2'-methoxycytosine, and g is 2'-methoxyguanine. In the present invention, the * between A, U, C, G, T, etc. indicates that the two nucleotides are connected by a phosphorothioate bond. For example, "A*dU g A Uf G" represents the sequence AUGAUG, starting from the 5' end, where the nucleotides at positions 1 and 2 are connected by a phosphorothioate diester bond, the nucleotide at position 2 is deoxyribonucleic acid, the nucleotide at position 3 is modified with a 2'-methoxy group, and the nucleotide at position 5 is modified with a 2'-fluoro group.

[0089] In some embodiments, the sense strand of the siRNA provided herein has 21 nucleotides, of which 18 are 2'-methoxy-modified nucleotides and 3 are 2'-fluoro-modified nucleotides; and the antisense strand has 21 nucleotides, of which 13 are 2'-methoxy-modified nucleotides and 8 are 2'-fluoro-modified nucleotides. In some embodiments, the sense strand of the siRNA provided by the present invention has 21 nucleotides, and the 1st to 8th and 12th to 21st nucleotides at the 5' end of the sense strand are 2'-methoxy-modified nucleotides, and the 9th to 11th nucleotides are 2'-fluorine-modified nucleotides; and / or the antisense strand of the siRNA provided by the present invention has 21 nucleotides, and the 1st, 3rd, 5th, 7th to 11th, 13th, 15th, 17th, 19th and 21st nucleotides at the 5' end of the antisense strand are 2'-methoxy-modified nucleotides, and the 2nd, 4th, 6th, 12th, 14th, 16th, 18th and 20th nucleotides are 2'-fluorine-modified nucleotides.

[0090] In the present invention, siRNA may include abasic nucleotides. As used herein, the term "abasic" refers to a lack of bases or a portion having other chemical groups replacing 1' bases. In some embodiments, abasic nucleotides may be inverted abasic nucleotides. In some embodiments, the 3' end and / or 5' end of the sense strand of siRNA include abasic nucleotides (e.g., inverted abasic nucleotides). In some embodiments, the 3' end and 5' end of the sense strand of siRNA include inverted abasic nucleotides. In some embodiments, the 5' end of the sense strand of siRNA includes inverted abasic nucleotides.

[0091] In the present invention, siRNA can include one or more modified internucleoside linkages (including the connection between siRNA and the ligand group, and the connection with the abasic nucleotide at the 3' end and / or the 5' end). In some embodiments, the modified internucleoside linkage includes a modified phosphate group, such as a thiophosphate, a selenophosphate, a borane phosphate, a hydrogen phosphonate, a phosphoramidate, an alkyl or aryl phosphonate, or a dithiophosphate. In some embodiments, siRNA can include one or more phosphorothioate-modified internucleoside linkages (including the connection between siRNA and the ligand group, and the connection with the abasic nucleotide at the 3' end and / or the 5' end).

[0092] In some embodiments, the sense strand of siRNA includes phosphorothioate-modified internucleoside linkages (including the connection between siRNA and the ligand group, and the connection with the abasic nucleotide at the 3' end and / or 5' end). In some embodiments, the sense strand of siRNA is phosphorothioate at the 3' end and the 5' end and the connection with the inverted abasic nucleotide, and other internucleoside linkages (including the connection between siRNA and the ligand group) are phosphodiester. In some embodiments, the sense strand of siRNA is phosphorothioate at the 3' end and the 5' end and the connection with the inverted abasic nucleotide and the 3' end and the connection between the inverted abasic nucleotide and the ligand group, and other internucleoside linkages are phosphodiester. In some embodiments, the sense strand of siRNA is phosphorothioate at the 5' end and the connection with the inverted abasic nucleotide, and other internucleoside linkages (including the connection between siRNA and the ligand group) are phosphodiester.

[0093] In some embodiments, the antisense strand of the siRNA comprises phosphorothioate-modified internucleoside linkages. In some embodiments, the linkages between the first and second, second and third, third and fourth, and 20th and 21st nucleotides at the 5' end of the antisense strand of the siRNA are phosphorothioate, and all other internucleoside linkages are phosphodiester.

[0094] In the present invention, siRNA may include a 5'-terminal phosphate or phosphate analog modification. 5'-phosphate modifications include those that are compatible with RISC-mediated gene silencing. Suitable modifications include: 5'-monophosphate ((HO)2(O)P—O-5'); 5'-diphosphate ((HO)2(O)P—O—P(HO)(O)—O-5'); 5'-triphosphate ((HO)2(O)P—O—(HO)(O)P—O—P(HO)(O)—O-5'); 5'-guanosine cap (7-methylated or unmethylated) (7m-GO-5'-(HO)(O)P—O—(HO)(O)P—O—P(HO)(O)—O-5'); 5'-adenosine cap (Appp), and any modified or unmodified nucleotide cap structure (N—O-5'-(HO)(O)P—O—(HO)(O)P—O—P(HO)(O)—O-5'); 5'-monothioate (phosphorothioate; (HO)2(S) P—O-5'); 5'-monodithioic acid esters (phosphorodithioate; (HO)(HS)(S)P—O-5'), 5'-thiophosphate ((HO)2(O)P—S-5'); any combination of monophosphates, diphosphates, and triphosphates with additional oxygen / sulfur substitutions (e.g., 5'-α-thiotriphosphate, 5'-γ-thiotriphosphate, etc.), 5'-phosphoramidates ((HO)2(O)P—NH-5', (HO)(NH2)(O)P—O-5'), 5'-alkylphosphonates (R = alkyl = methyl, ethyl, isopropyl, propyl, etc., e.g., RP(OH)(O)—O-5'-, (OH)2(O)P-5'-CH2-), 5'vinylphosphonates, 5'-alkyletherphosphonates (R = alkylether = methoxymethyl (MeOCH2 - ), ethoxymethyl, etc., for example, RP(OH)(O)—O-5'-). In some embodiments, the 5' end of the antisense strand of the siRNA includes a 5' vinylphosphonate (VP) modification. Suitable phosphate modifications include 5'-cyclic phosphonates, as disclosed in international application WO2017214112A1. In some embodiments, the 5' end of the antisense strand of the siRNA includes a 5' cyclopropylphosphonate (cPrP) modification.

[0095] In the present invention, "pharmaceutically acceptable carrier" may include, but is not limited to, excipients, and / or other components. An "excipient" is a pharmaceutically acceptable solvent, suspending agent, or any other pharmaceutically inert medium for delivering one or more nucleic acids to an animal. Such agents are well known in the art. The compositions of the present invention may additionally contain other auxiliary components conventionally present in pharmaceutical compositions at established usage levels in the art. Thus, for example, the composition may contain additional, compatible pharmaceutically active substances, such as antipruritic agents, astringents, local anesthetics, or anti-inflammatory agents, or may contain additional substances that can be used to physically formulate various dosage forms of the compositions of the present invention, such as preservatives, antioxidants, and stabilizers. However, when added, such substances should not unduly interfere with the biological activity of the components of the compositions of the present invention. The formulations may be sterilized and, if desired, may be mixed with adjuvants that do not deleteriously interact with the nucleic acids of the formulations, such as preservatives, stabilizers, wetting agents, emulsifiers, salts that affect osmotic pressure, or buffers.

[0096] In the present invention, siRNA or siRNA conjugates can be incorporated into a delivery vehicle, such as a liposome or a particle. Typically, as described herein, the siRNA composition is formulated in a manner compatible with the intended method of administration. For example, in specific embodiments, the composition is prepared by at least one of the following methods: spray drying, freeze drying, vacuum drying, evaporation, fluidized bed drying, or a combination of these techniques; or sonication with a lipid, freeze drying, condensation, or other self-assembly.

[0097] In the present invention, the term "liposome" refers to a vesicle composed of amphiphilic lipids and arranged in at least one bilayer (e.g., one or more bilayers). Liposomes include unilamellar and multilamellar vesicles having a membrane formed by a lipophilic material and an aqueous interior. The aqueous portion contains the siRNA or siRNA conjugate. The lipophilic material separates the aqueous interior from an aqueous exterior, which typically does not include the siRNA or siRNA conjugate, but in some instances, may do so. Liposomes are suitable for transferring and delivering active ingredients to the site of action. Because the liposome membrane is structurally similar to biological membranes, when liposomes are administered to a tissue, the liposome bilayer fuses with the bilayer of the cell membrane. As the fusion of the liposome and the cell proceeds, the internal aqueous contents, including the siRNA or siRNA conjugate, are delivered to the cell, where the siRNA or siRNA conjugate can specifically bind to a target RNA and mediate RNAi. In some cases, these liposomes are also specifically targeted, for example, to direct the siRNA or siRNA conjugate to a specific cell type.

[0098] An siRNA formulation can be formulated in combination with another agent, such as another therapeutic agent or an agent that stabilizes the siRNA, such as a protein that complexes with the siRNA to form an iRNP. Still other agents include chelating agents such as EDTA (e.g., to remove divalent cations such as Mg 2+ )), salts, RNase inhibitors (e.g., a broad specificity RNase inhibitor, such as RNAsin), and the like.

[0099] In some embodiments, the siRNA formulation includes another siRNA compound, for example, a second siRNA that mediates RNAi against a second gene or against the same gene. Other formulations can include at least 3, 5, 10, 20, 50, or 100 or more different siRNA species. Such siRNAs can mediate RNAi against a similar number of different genes.

[0100] In some embodiments, the siRNA formulation includes at least one second therapeutic agent (e.g., an agent other than an RNA or a DNA). In some embodiments, the second therapeutic agent comprises a drug for treating IgA nephropathy, autoimmune diseases caused by complement activation, autoimmune diseases, or diseases associated with CFB expression.

[0101] The iRNA agents of the present invention can be formulated for pharmaceutical use. Pharmaceutically acceptable compositions include a therapeutically effective amount of one or more of the dsRNA agents of any of the above embodiments, alone or in combination with one or more pharmaceutically acceptable carriers (additives), excipients, and / or diluents.

[0102] The pharmaceutical compositions can be specifically formulated for administration in solid or liquid form, including forms suitable for: (1) oral administration, such as drenches (aqueous or non-aqueous solutions or suspensions), tablets (e.g., tablets targeted for buccal, sublingual, and systemic absorption), boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, such as by subcutaneous, intramuscular, intravenous, or epidural injection, as, for example, a sterile solution or suspension or a sustained-release formulation; (3) topical administration, such as in the form of a cream, ointment, or a controlled-release patch or spray applied to the skin; (4) intravaginally or intrarectally, such as in the form of a pessary, cream, or foam; (5) sublingually; (6) ocularly; (7) transdermally; or (8) nasally. Delivery using subcutaneous or intravenous methods can be particularly advantageous.

[0103] A composition comprising an iRNA can be delivered to a subject by a variety of routes. Exemplary routes include intravenous, subcutaneous, topical, rectal, anal, vaginal, nasal, pulmonary, and ocular.

[0104] The compositions of the present invention can be administered in a variety of ways, depending on whether local or systemic treatment is desired and on the area to be treated. Administration can be topical (including ocular, vaginal, rectal, intranasal, transdermal), oral, or parenteral. Parenteral administration includes subcutaneous injection, intravenous drip, intravenous injection, intraperitoneal or intramuscular injection, or intrathecal or intraventricular administration.

[0105] The route and site of administration can be selected to enhance targeting. For example, to target muscle cells, intramuscular injection into the muscle of interest would be a logical choice. Pneumocytes can be targeted by administering the iRNA in aerosol form. Vascular endothelial cells can be targeted by coating a balloon catheter with the iRNA and mechanically introducing the DNA.

[0106] The abbreviations or abbreviations used in the present invention are as follows:

[0107] (invAb) is an inverted abasic RNA, VP is vinylphosphonate, and cPrP is cyclopropylphosphonate. BRIEF DESCRIPTION OF THE DRAWINGS

[0108] Figure 1 shows the results of the test of the inhibitory activity of a single dose of double-stranded RNA conjugate on the intrahepatic target gene CFB in humanized CFB mice.

[0109] FIG2 shows the results of a single-dose double-stranded RNA conjugate inhibitory activity test on the hepatic target gene CFB in humanized CFB mice (28 days).

[0110] FIG3 shows the results of a single-dose double-stranded RNA conjugate inhibitory activity test on the hepatic target gene CFB in cynomolgus monkeys.

[0111] FIG4 shows the results of a single-dose double-stranded RNA conjugate inhibitory activity test on the intrahepatic target mRNA CFB in cynomolgus monkeys.

[0112] FIG5 shows the results of the inhibitory activity test of a single dose of double-stranded RNA conjugate against the serum target protein CFB in cynomolgus monkeys. DETAILED DESCRIPTION

[0113] The following examples are provided to illustrate the present invention and are intended to provide a better understanding of the present invention, but are not intended to limit the scope of the present invention. Modifications or variations to the elements of the present invention without departing from the spirit and substance of the present invention are considered to be within the scope of the present invention. Unless otherwise specified, the reagents, kits, and biological materials used in the present invention are commercially available. Kits used in the present invention were used according to the kit instructions unless otherwise specified.

[0114] Example 1: Synthesis of siRNA molecules

[0115] Oligoribonucleotides were synthesized using the phosphoramidite solid-phase synthesis technique. Synthesis was performed on universal controlled pore glass (CPG). All 2'-modified RNA phosphoramidites and auxiliary reagents were commercially available. All phosphoramidites were dissolved in anhydrous acetonitrile and molecular sieves were added. The coupling time was 1.0 min using 5-ethylthio-1H-tetrazole (ETT) as an activator. Phosphorothioate bonds were generated using a 50 mM solution of 3-((dimethylamino-methylene)amino)-3H-1,2,4-dithiazole-3-thione (DDTT) in anhydrous acetonitrile / pyridine (v / v = 1 / 1) with a reaction time of 1.8 min. All sequences were synthesized after the final removal of the DMT group.

[0116] Cleavage and deprotection of oligomers bound to CPG: After solid-phase synthesis is completed, the protecting groups are removed by treatment with acetonitrile containing 20% ​​diethylamine for 30 minutes, without cleaving the oligonucleotide from the CPG. Subsequently, the dried CPG is treated with concentrated aqueous ammonia at 40 degrees Celsius for 18 hours. After centrifugation, the supernatant is transferred to a new tube and the CPG is washed with aqueous ammonia. The combined solution is concentrated to obtain a solid mixture.

[0117] Purification of single-stranded oligoribonucleotides: Oligomers were purified by HPLC using a NanoQ anion exchange column. Buffer A consisted of 10 mM sodium perchlorate, 20 mM Tris, 1 mM EDTA, pH 7.4, and 20% acetonitrile, and buffer B consisted of 500 mM sodium perchlorate, 20 mM Tris, 1 mM EDTA, pH 7.4, and 20% acetonitrile. The desired product was isolated and desalted using a reversed-phase C18 column.

[0118] Annealing of single-stranded oligoribonucleotides to produce siRNA: Prepare the single-stranded oligoribonucleotides to be annealed at a concentration of 200 μM using sterile RNase-free H2O (RNA hydrolase-free). Set up the annealing reaction as follows: Place 10 nmol of the mixture in a 95°C water bath for 10 minutes (amounts ≥ 100 nmol require 20 minutes at high temperature). Immediately place the mixture in a 60°C water bath and allow to cool naturally. Do not store the annealed solution at high temperatures. Complementary strands are formed by combining equimolar amounts of the single-stranded oligoribonucleotide solutions.

[0119] Example 2: Evaluation of the in vitro inhibitory activity of siRNA compounds on the target gene CFB

[0120] 1. Research Objectives

[0121] The purpose of this study was to evaluate the in vitro inhibitory activity of siRNA compounds against the target gene CFB.

[0122] 2. Materials and Methods

[0123] 2.1 Materials

[0124] 2.1.1 Test compounds

[0125] Test compound: Prepared into 20 μM stock solution in PBS.

[0126] 2.1.2 Cell lines

[0127] Huh7 cells were provided by Shanghai WuXi AppTec Pharmaceutical Development Co., Ltd. Huh7 cells were cultured in Dulbecco's Modified Eagle Medium (Gibco No. 11965-092) supplemented with 10% fetal bovine serum (FBS, ExCell Bio Product No. FSP500), 1% glutamine (GlutaMAX, Gibco Product No. 35050061), 1% NEAA (Gibco Product No. 11140050), and 1% penicillin-streptomycin (HyClone Product No. SV30010).

[0128] 2.1.3 Main instruments

[0129] The main instruments used in this experiment include a fluorescence qPCR instrument (Quanstudio 7flex), a centrifuge (Beckman Allegra-X15R Centrifuge), and a cell counter (Countstar Rigel2).

[0130] 2.1.4 Main reagents and consumables

[0131] The main reagents used in this experiment include Lipofectamine TM iRNAiMAX transfection reagent (INVITROGEN, cat. no. 13778150), Faststart Universal SYBR Green Master (ROCHE cat. no. 4913914001), RNA extraction kit (Qiagen, cat. no. 74182), FastKing cDNA first-strand synthesis kit (TianGen, cat. no. KR116-02), and 96-well plates (Costar 3599). qPCR-specific primers for GAPDH and CFB were synthesized by Shanghai Sangon Biotechnology.

[0132] 3. Experimental Methods

[0133] 3.1 Compound transfection and plating

[0134] Huh7 cells (2×10⁴ cells / well) were seeded into 96-well plates and transfected with siRNA using RNAiMAX. Two siRNA concentrations (10 nM and 0.5 nM) were tested. The cells were incubated overnight at 37°C in a 5% CO₂ incubator. The assay was performed in duplicate. A control group containing RNAiMAX and no compound was also established.

[0135] 3.2 RNA extraction and reverse transcription

[0136] 24 hours after transfection, the culture medium was removed and the cells were collected for RNA extraction. Total RNA was extracted using QIAGEN-74182 RT Kit and cDNA was synthesized using the FastKing RT Kit (with gDNase) (Tiangen-KR116-02) according to the manufacturer's instructions.

[0137] 3.3 Detection of target gene mRNA expression levels by qPCR

[0138] Target cDNA will be detected by SYBR Green qPCR, with GAPDH cDNA used in parallel as an internal control. 8 μL of the prepared PCR reaction solution and 2 μL of sample cDNA will be added to a 384-well plate. The qPCR reaction program is as follows: 50°C for 2 minutes, 90°C for 10 minutes, followed by cycling, 95°C for 15 seconds, and 60°C for 1 minute, for a total of 40 cycles.

[0139] 2.2.3 Data Analysis

[0140] The target gene mRNA expression level for each sample was calculated using the ΔΔCt relative quantification method. The relative expression of the target gene was expressed as 2-ΔΔCT.

[0141] The calculation formula is as follows:

[0142] ΔCT = average Ct value of target gene - average Ct value of reference gene

[0143] ΔΔCT = ΔCT (drug-treated group) - ΔCT (RNAiMAX control group)

[0144] Relative expression of target gene CFB = 2-ΔΔCT

[0145] CFB inhibition rate % = (1-value of sample / Ave.value of RNAiMAX Control) * 100

[0146] GraphPad Prism software was used for graphical analysis, and the inhibition rate results were expressed as mean ± SD.

[0147] The test results are shown in Table 3-5 below.

[0148] Table 3 In vitro inhibitory activity of siRNA compounds on the target gene CFB

[0149] Table 4 Dose-dependent inhibitory activity of siRNA compounds on the target gene CFB in huh7 cells

[0150] Table 5 IC values ​​of double-stranded RNA conjugates for target gene CFB mRNA in huh7 cells 50

[0151] Test conclusion:

[0152] The siRNA molecules reported in the present disclosure can significantly suppress the level of CFB mRNA in cells.

[0153] Example 3: Activity test of double-stranded RNA conjugate on target gene CFB in primary human hepatocytes (PHH)

[0154] 1. Test compound

[0155] Test compound: Prepared into 100 μM / 200 μM stock solution in PBS.

[0156] 2. Cells

[0157] Primary human hepatocytes (PHH) (Lot No. JMJ) were provided by Shanghai WuXi AppTec Pharmaceutical Development Co., Ltd. PHH were revived and cultured in InvitroGRO CP medium (BIOIVT Catalog No. S0331) supplemented with 10% fetal bovine serum (FBS, Gibco Catalog No. 10091148) and 1% penicillin-streptomycin (PS, HyClone Catalog No. SV30010).

[0158] 3. Main instruments

[0159] The main instruments used in this experiment include a fluorescence qPCR instrument (Quanstudio 7flex), a centrifuge (Beckman Allegra-X15R Centrifuge), and a cell counter (Countstar Rigel2).

[0160] 4. Main reagents and consumables

[0161] The main reagents used in this experiment include Faststart Universal SYBR Green Master (ROCHE Catalog No. 4913914001), RNA extraction kit (Qiagen Catalog No. 74182), HiScript III RT SuperMix for qPCR (+gDNA wiper) (Vazyme Catalog No. R323-01), 96-well plate (Costar Catalog No. 3599), and qPCR-specific primers for GAPDH and CFB were synthesized by Shanghai Sangon Biotechnology.

[0162] 5. Experimental Methods

[0163] 5.1 Compound Free Uptake Plating

[0164] Inoculate PHH (5.4×10 4 Cells were plated at 100 cells / well in a 96-well plate. siRNA was added to the cells simultaneously with the plating. Compounds were allowed to enter the cells through free uptake. Three concentrations (10 nM, 1 nM, and 0.1 nM) were set for the siRNA assay and assayed in triplicate. A control group containing PBS and no compound was also established. Cells were then cultured in a 37°C, 5% CO2 incubator.

[0165] 5.2 RNA extraction and reverse transcription

[0166] After 48 hours, the culture medium was removed and the cells were collected for RNA extraction. Total RNA was extracted using QIAGEN 96 Kit (QIAGEN-74182), and cDNA was synthesized using HiScript III RT SuperMix for qPCR (+gDNA wiper) (Vazyme Product No. R323-01) according to the manufacturer's instructions.

[0167] 5.3 Detection of target gene mRNA expression levels by qPCR

[0168] The target cDNA will be detected by qPCR, along with the reference gene GAPDH cDNA. 8 μL of the prepared PCR reaction solution and 2 μL of sample cDNA are added to a 384-well plate. The qPCR reaction program is as follows: 50°C for 2 minutes, 95°C for 10 minutes, followed by cycling at 95°C for 15 seconds, followed by 60°C for 1 minute, for a total of 40 cycles, and finally, heating at 60°C for 1 minute and 95°C for 15 seconds.

[0169] Table 6 Inhibition rate of double-stranded RNA conjugates on target gene CFB mRNA in primary human hepatocytes

[0170] Table 7 IC50 of double-stranded RNA conjugates against target gene CFB mRNA in primary human hepatocytes

[0171] Example 4: In vivo inhibitory activity test of the compound on the target gene CFB in human CFB tail artery injected (HDI) mice CFB plasmid DNA

[0172] The pcDNA-CFB plasmid was provided by Shanghai WuXi AppTec Pharmaceutical Development Co., Ltd. with the batch number 80-745026323-R3 / PA21797-4 N1024958. The concentration was 4.3 μg / μL and it was diluted with normal saline for later use.

[0173] Reagents and consumables

[0174] The main reagents and consumables are shown in the table below.

[0175] Main reagents and consumables

[0176] Experimental methods

[0177] In vivo experiments

[0178] The in vivo experimental design for CFB plasmid DNA tail vein high-pressure injection, drug administration, and sample collection methods are shown in Table 4.

[0179] Compound treatment: The day mice were dosed was defined as day 0, the day before was day -1, the day after was day 1, and so on. On day 0, mice were subcutaneously injected with the solvent or test compound at a volume of 5 mL / kg. Detailed information is shown in Table 4.

[0180] Mice were injected with CFB plasmid DNA solution via tail vein hyperbaric injection: On day 3 or 14, plasmid DNA was prepared in normal saline and stored at 4°C until use. All mice were injected with 10 μg of plasmid DNA solution (8% of their body weight) via the tail vein within 5 seconds (injection volume (mL) = mouse weight (g) × 8%).

[0181] Experimental endpoint and liver sample collection: On day 4 or 15, 24 hours after high-pressure tail vein injection of CFB plasmid, all mice were euthanized by CO2 inhalation. After euthanasia, blood was collected from the heart and liver samples were collected. Two 70 mg portions of liver tissue were immersed in After incubation at 4°C overnight, the supernatant was discarded and transferred to a -80°C refrigerator for mRNA detection.

[0182] Sample analysis

[0183] Detection of CFB gene expression in mouse liver by quantitative PCR

[0184] RNA from the liver was extracted using Trizol. The method is briefly described as follows: 50-70 mg of liver tissue and 1.2 mL of Trizol were homogenized using a Qiagen Tissue Lyser II at 26 Hz for 2 minutes. Lysis was performed at room temperature for 5 minutes. 1 mL of the supernatant was collected, 200 μL of chloroform was added, and the mixture was vigorously shaken for 15 seconds. After standing for 3 minutes, the supernatant was centrifuged and collected. An equal volume of isopropanol was added and the mixture was precipitated overnight at -20°C. The mixture was washed twice with 70% ethanol and dissolved in RNase-free water. The RNA sample concentration was determined using a Nanodrop ONE and diluted to 400 ng / μL with RNase-free water for reverse transcription.

[0185] The reverse transcription experimental steps refer to the FastKing cDNA First Strand Synthesis Kit (Genomic Depletion) instructions. A brief description is as follows: Prepare the gDNA removal mixture according to the table below. Add the mixture (5 μL / sample) and 400 ng / μL RNA sample to a 96-well PCR reaction plate, incubate at 42°C for 3 minutes, and cool on ice. Prepare the reverse transcription mixture according to the table below. Add the reverse transcription mixture (10 μL / sample) and the DNA removal product from the previous step to a 96-well PCR reaction plate and perform reverse transcription. Reaction conditions: 42°C for 15 minutes; 95°C for 3 minutes. Store the cDNA at 4°C for further analysis.

[0186] gDNA-removal reaction components table

[0187] RT-PCR reaction components table

[0188] The quantitative PCR method for detecting CFB and NEO gene expression in mouse liver is briefly described as follows: Prepare the qPCR reaction mixture as shown in the table below, add 2 μL of the cDNA sample diluted 4-fold with RNase-free water, and perform the PCR reaction. Reaction conditions: 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.

[0189] qPCR Reaction Components Table (CFB)

[0190] qPCR Reaction Components Table (NEO)

[0191] The ΔΔCt method was used to analyze the expression of the target gene in each test sample. This method measures the Ct difference (ΔCt) between the target gene (CFB) and the reference gene (Neo), and compares the ΔCt values ​​of the compound-treated sample with those of the control group. The formula is:

[0192] ΔCt = average Ct value of target gene - average Ct value of reference gene.

[0193] ΔΔCt = ΔCt of compound-treated samples - average ΔCt of the control group.

[0194] Gene expression level = 2 -ΔΔCT

[0195] Data analysis. Data are expressed as mean ± standard error of each mouse sample group, n = 4 or 5 unless otherwise specified. Statistical analysis was performed using Student's t test.

[0196] Table 8 Test results of the inhibitory activity of the compounds on the target gene CFB after 4 days of administration

[0197] Table 9 Inhibitory activity test results of the compounds on the target gene CFB after 15 days of administration

[0198] Table 10 Inhibitory activity test results of the compounds on the target gene CFB after 15 days of administration

[0199] Example 5: Inhibitory activity test of the compound on the target gene CFB in human CFB knock-in mice (hCFB)

[0200] animal

[0201] B6-hCFB (C57BL / 6JSmoc-Cfbtm1(hCFB) / Smoc male) were purchased from Southern Model Organisms Science Co., Ltd. Blood was collected on Day 1 and mice were randomly divided into groups according to body weight. After administration on Day 0, blood was collected weekly for serum separation (4 hours of fasting before each blood collection) for 28 days to detect the expression of the target protein in the serum. At the end of the 28-day experiment, mouse livers were collected for RT-PCR detection of mouse CFB expression, and eye plasma was used to test the expression of the target protein CFB.

[0202] Protein detection:

[0203] The human CFB ELISA kit was from Abcam (Cat. No. ab137973). All experiments were performed in strict accordance with the instructions of the ELISA kit.

[0204] Experimental instruments:

[0205] The experimental results are shown in Tables 11, 12 and Figures 1 and 2.

[0206] Table 11 In vivo inhibitory activity test results of compounds against serum target protein CFB in hCFB mice

[0207] Table 12 In vivo inhibitory activity of compounds against liver target mRNA CFB in hCFB mice

[0208] Example 6: Inhibitory activity of a single dose of double-stranded RNA conjugate against the target gene CFB in cynomolgus monkeys Test animals:

[0209] Elution monkeys: Age: 5.2-8.9 years; Weight: 2.5-5 kg;

[0210] Main reagents and consumables

[0211] Experimental methods:

[0212] The in vivo experimental design of subcutaneous injection, drug administration and sample collection methods of elution monkeys is shown in the table below.

[0213] Compound treatment: The day of administration of the washout monkey was defined as day 0, the day before was day -1, the day after was day 1, etc. On day 0, the monkeys were subcutaneously injected with the solvent or the test compound at a volume of 0.5 mL / kg.

[0214] Liver samples were collected on Day-1, Day 28, and Day 56. Sampling method: Animals were fasted for 12-16 hours before sampling. Cynomolgus monkeys were anesthetized by intramuscular injection of atropine sulfate injection (0.05 mg / kg) + Zotadine 50 (4-6 mg / kg). Zotadine 50 was injected approximately 15 minutes after the administration of atropine sulfate injection. After the initial anesthesia, the observation time was extended as much as possible. Pain response (finger pinch test) could be used to determine the severity of the pain.

[0215] Additional Shutai 50 anesthetic preparation (add 1 / 3 of the initial anesthesia). After anesthesia, carefully remove the epidermal hair with a shaver, apply coupling agent to the location to be tested, use a flat array probe, adjust the frequency to 10 MHz to locate the liver, and use a disposable biopsy needle under B-ultrasound guidance to penetrate the skin to the surface of the liver (the biopsy needle can be seen under B-ultrasound) and puncture the liver parenchyma (avoiding areas rich in liver veins). Liver tissue is collected according to the animal's condition. Each tissue sample collected by needle is stored in a separate cryopreservation tube and weighed. After sampling, the needle is withdrawn and ten cotton balls are used to press on the puncture site for 5 minutes to stop bleeding. After hemostasis, B-ultrasound is used again to observe liver bleeding;

[0216] Sample processing method: Liver puncture samples were immediately immersed in 1.5 mL of EP containing RNAlater after removal and placed at 4°C overnight. The remaining liquid was aspirated the next day and the samples were immediately stored at -60°C or below until shipped to WuXi AppTec's Pharmacodynamics Department for testing under dry ice.

[0217] In vivo experimental design

[0218] Quantitative PCR detection of CFB gene expression in monkey liver:

[0219] RNA was extracted from the liver using Trizol. RNA sample concentration was determined using a Nanodrop ONE (ultra-micro-volume UV-visible spectrophotometer) and diluted to 400 ng / μL with RNase-free water for reverse transcription. Quantitative PCR was used to determine the expression of CFB and NEO genes in monkey liver.

[0220] Experimental results: See Tables 13, 14 and Figures 3, 4.

[0221] Table 13 Results of the inhibitory activity test of a single dose of double-stranded RNA conjugate on the hepatic target gene CFB in cynomolgus monkeys

[0222] All values ​​were normalized to the group mean on day −1.

[0223] Table 14 Results of the inhibitory activity test of a single dose of double-stranded RNA conjugate against the intrahepatic target mRNA CFB in cynomolgus monkeys

[0224] Protein detection CFB protein expression in monkey serum:

[0225] The human CFB ELISA kit was from Abcam (Cat. No. ab137973). All experiments were performed in strict accordance with the instructions of the ELISA kit.

[0226] Experimental instruments:

[0227] Experimental results: See Table 15 and Figure 5.

[0228] Table 15 Inhibitory activity test results of single-dose double-stranded RNA conjugate against serum target protein CFB in cynomolgus monkeys

[0229] Conclusion: The double-stranded RNA conjugate dS308 of the present invention effectively inhibited the expression of the target gene CFB.

Claims

1. An siRNA, comprising a sense strand and an antisense strand, wherein at least a portion of the sense strand and at least a portion of the antisense strand are reverse complementary to each other and form a double-stranded region, in, The sense strand comprises a sequence as shown in any one of SEQ ID NOs: 1-96 and SEQ ID NOs: 194-195.

2. An siRNA, comprising a sense strand and an antisense strand, wherein at least a portion of the sense strand and at least a portion of the antisense strand are reverse complementary to each other and form a double-stranded region, in, The antisense strand comprises a sequence as shown in any one of SEQ ID NOs: 97-192 and SEQ ID NOs: 196-197.

3. The siRNA according to claim 1 or 2, in, The sense strand comprises 17 to 21 (further 20 consecutive) bases in a sequence as shown in SEQ ID NO:20, SEQ ID NO:194 or SEQ ID NO:195, and the antisense strand comprises 17 to 21 (further 20 consecutive) bases in a sequence as shown in SEQ ID NO:116, SEQ ID NO:196 or SEQ ID NO:

197.

4. The siRNA according to claim 3, in, a) the sense strand comprises the sequence shown in SEQ ID NO:20, and the antisense strand comprises the sequence shown in SEQ ID NO:116; or b) the sense strand of the siRNA comprises the sequence shown in SEQ ID NO: 195, and the antisense strand comprises the sequence shown in SEQ ID NO: 197; or c) the sense strand comprises the sequence shown in SEQ ID NO:20, and the antisense strand comprises the sequence shown in SEQ ID NO:

197.

5. The siRNA according to any one of claims 1 to 4, in, The siRNA comprises one or more modified nucleotides; further, all nucleotides are modified nucleotides.

6. The siRNA according to claim 5, in, The modified nucleotides are selected from 2'-methoxy modified nucleotides or 2'-fluoro modified nucleotides.

7. The siRNA according to any one of claims 1 to 6, in, The siRNA comprises an abasic nucleotide; optionally, the abasic nucleotide is an inverted abasic nucleotide.

8. The siRNA according to claim 7, in, The 5' end of the sense strand of the siRNA comprises the abasic nucleotide.

9. The siRNA according to any one of claims 1 to 8, in, The siRNA includes one or more modified internucleoside linkages.

10. The siRNA according to claim 9, in, The modified internucleoside linkages are phosphorothioates.

11. The siRNA according to any one of claims 1 to 10, in, The siRNA includes a 5' terminal phosphate or a phosphate analog modification; further, the 5' end of the antisense strand of the siRNA includes a 5' terminal phosphate or a phosphate analog modification.

12. The siRNA according to claims 1 to 11, in, The phosphate analog modification is a vinylphosphonate (VP) modification.

13. The siRNA according to claim 1 or 2, in, siRNA was selected from dS183-dS278.

14. The siRNA according to claim 1 or 2, in, The siRNA is selected from any one of the siRNAs shown in Table 2; further, selected from dS183, dS184, dS185, dS186, dS187, dS188, dS189, dS190, dS191, dS192, dS193, dS194, dS195, dS196, dS197, dS198, dS199, dS200, dS201, dS202, dS203, dS204, dS205, dS 206, dS207, dS208, dS209, dS210, dS211, dS212, dS213, dS214, dS215, dS216, dS217, dS218, dS219, dS 220, dS221, dS222, dS223, dS224, dS225, dS226, dS227, dS228, dS229, dS230, dS231, dS232, dS233, dS2 34. dS235, dS236, dS237, dS238, dS239, dS240, dS241, dS242, dS243, dS244, dS245, dS246, dS247, dS2 48. dS249, dS250, dS251, dS252, dS253, dS254, dS255, dS256, dS257, dS258, dS259, dS260, dS261, dS26 2. dS263, dS264, dS265, dS266, dS267, dS268, dS269, dS270, dS271, dS272, dS273, dS274, dS275, dS276 , dS277, dS278, dS289, dS290, dS291, dS292, dS293, dS294, dS295, dS296, dS297, dS298, dS299 or dS300.

15. A siRNA conjugate, comprising the siRNA according to any one of claims 1 to 14 and a ligand group, wherein the ligand group is conjugated to the siRNA, the ligand group comprises 1, 2, 3 or 4 GalNAc groups, and the number of the ligand groups is 1, 2, 3, 4, 5, 6 or 7.

16. The siRNA conjugate according to claim 15, in, The ligand group is conjugated to the 3' end of the sense strand.

17. The siRNA conjugate according to any one of claims 15 to 16, in, The ligand group is selected from NAG37 or L96.

18. The siRNA conjugate according to any one of claims 15 to 17, in, The siRNA is selected from any one of the siRNA conjugates shown in Table 2; further selected from dS308, dS309, dS310, dS311, dS323, dS326, dS327, dS328, dS329, dS330, dS331, dS332, dS333 or dS334.

19. A pharmaceutical composition comprising the siRNA according to any one of claims 1 to 14 or the siRNA conjugate according to any one of claims 15 to 18, and a pharmaceutically acceptable carrier.

20. Use of the siRNA according to any one of claims 1 to 14 or the siRNA conjugate according to any one of claims 15 to 18 in the preparation of a drug for treating a disease associated with CFB expression; further, the disease associated with CFB expression is an autoimmune disease caused by complement activation; further, the disease associated with CFB expression is IgA nephropathy.

Citation Information

Patent Citations

  • Modulators of complement factor B

    CN105744959A

  • Complement component iRNA compositions and methods of use thereof

    CN105814205A

  • Compositions and methods for modulating Complement Factor B expression

    CN110724687A

  • Complement factor B (CFB) iRNA compositions and methods of use thereof

    CN116096381A

  • Nucleic acid inhibiting expression of complement factor b

    WO2018117253A1

Cited By

  • Small interfering RNA targeting CFB and uses thereof

    US12735709B2

  • Sirna, conjugate which contain sirna, pharmaceutical composition and uses thereof

    WO2026056988A1